|
2025 Journal Article Health-related quality-of-life outcomes with regorafenib in advanced gastric and esophagogastric junction cancer: results from the INTEGRATE trialsMartin, Andrew J., Soon, Yu Yang, Sjoquist, Katrin Marie, Pavlakis, Nick, Goldstein, David, Shitara, Kohei and Simes, John R. (2025). Health-related quality-of-life outcomes with regorafenib in advanced gastric and esophagogastric junction cancer: results from the INTEGRATE trials. Gastric Cancer. doi: 10.1007/s10120-025-01670-2 |
|
2025 Journal Article Barry J. Zimmerman's Enduring Legacy: The Inspiring Fusion of Self-Regulated Learning Theory, Practice, and MentorshipKitsantas, Anastasia, Bembenutty, Hefer, Cleary, Timothy J., Alexander, Patricia A., Dibenedetto, Maria K., Kaplan, Avi, Kolovelonis, Athanasios, Mandell, Brian E., Martin, Andrew J., Mccrudden, Matthew T., Panadero, Ernesto, Salisbury-Glennon, Jill D. and Schunk, Dale H. (2025). Barry J. Zimmerman's Enduring Legacy: The Inspiring Fusion of Self-Regulated Learning Theory, Practice, and Mentorship. Educational Psychology Review, 37 (3) 78. doi: 10.1007/s10648-025-10052-0 |
|
2025 Journal Article Oncologist and General Practitioner Perspectives of Shared Care for Colorectal Cancer Survivors: A Qualitative StudyLisy, Karolina, Tieu, Matthew, Gore, Claire, Schofield, Penelope, Chan, Raymond J., Emery, Jon, Martin, Andrew, De Abreu Lourenco, Richard and Jefford, Michael (2025). Oncologist and General Practitioner Perspectives of Shared Care for Colorectal Cancer Survivors: A Qualitative Study. Psycho-Oncology, 34 (7) e70223, 7. doi: 10.1002/pon.70223 |
|
2025 Journal Article INTEGRATE pooled phase II/III results are robust to post-progression switching and winner’s curseSoon, Yu Yang, Sjoquist, Katrin, Marschner, Ian C, Schou, I Manjula, Pavlakis, Nick, Goldstein, David, Shitara, Kohei, Stockler, Martin R, Simes, John and Martin, Andrew J (2025). INTEGRATE pooled phase II/III results are robust to post-progression switching and winner’s curse. JNCI Cancer Spectrum, 9 (4) pkaf053. doi: 10.1093/jncics/pkaf053 |
|
2025 Conference Publication 177 Lu-PSMA-617 with ipilimumab (ipi) and nivolumab (nivo) in metastatic castration-resistant prostate cancer (mCRPC): An investigator-initiated phase 2 trial (EVOLUTION; ANZUP2001)Sandhu, Shahneen, Subramaniam, Shalini, Thomas, Hayley, Tan, Thean Hsiang, Goh, Jeffrey C., Dhiantravan, Nattakorn, Weickhardt, Andrew James, Joshua, Anthony M., Kirkwood, Ian David, Lee, Sze Ting, Gedye, Craig, Nguyen, Andrew, Pattison, David A., Alipour, Ramin, Francis, Roslyn J., Hofman, Michael S., Martin, Andrew James, Stockler, Martin R., Davis, Ian D., Emmett, Louise and The Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) (2025). 177 Lu-PSMA-617 with ipilimumab (ipi) and nivolumab (nivo) in metastatic castration-resistant prostate cancer (mCRPC): An investigator-initiated phase 2 trial (EVOLUTION; ANZUP2001). 2025 ASCO Annual Meeting I, Chicago, IL, United States, 30 May - 3 June 2025. Alexandria, VA, United States: American Society of Clinical Oncology. doi: 10.1200/jco.2025.43.16_suppl.5016 |
|
2025 Conference Publication Association of circulating immune and metabolic markers with clinical outcomes in the ENZAMET trial (ANZUP 1304)Horvath, Lisa, Lin, Hui-Ming, Davis, Ian D., Martin, Andrew James, Yeung, Nicole, Kim, Rachel MN, Portman, Neil, Joshua, Anthony M., McJannett, Margaret Mary, Subhash, Vinod, Yip, Sonia, North, Scott A., McDermott, Raymond S., Chi, Kim N., Stockler, Martin R., Sweeney, Christopher and The Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) (2025). Association of circulating immune and metabolic markers with clinical outcomes in the ENZAMET trial (ANZUP 1304). 2025 ASCO Annual Meeting, Chicago, IL, United States, 30 May - 3 June 2025. Alexandria, VA, United States: American Society of Clinical Oncology. doi: 10.1200/jco.2025.43.16_suppl.5093 |
|
2025 Conference Publication Clonal hematopoiesis (CH) in participants with metastatic castration-resistant prostate cancer (mCRPC) receiving 177 Lu-PSMA-617 or cabazitaxel: An exploratory post-hoc analysis of a randomized phase II trial (TheraP; ANZUP 1603)Munzur, Aslı Doğa, Herberts, Cameron, Kwan, Edmond Michael, Emmett, Louise, Sandhu, Shahneen, Buteau, James Patrick, Iravani, Amir, Joshua, Anthony M., Francis, Roslyn J., Lee, Sze Ting, Scott, Andrew Mark, Martin, Andrew James, Stockler, Martin R., Zhang, Alison Yan, Williams, Scott G., Bacon, Jack V.W., Azad, Arun, Davis, Ian D., Hofman, Michael S., Wyatt, Alexander William and The Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) (2025). Clonal hematopoiesis (CH) in participants with metastatic castration-resistant prostate cancer (mCRPC) receiving 177 Lu-PSMA-617 or cabazitaxel: An exploratory post-hoc analysis of a randomized phase II trial (TheraP; ANZUP 1603). 2025 ASCO Annual Meeting I, Chicago, IL, United States, 30 May - 3 June 2025. Alexandria, VA, United States: American Society of Clinical Oncology. doi: 10.1200/jco.2025.43.16_suppl.5020 |
|
2025 Conference Publication Predictive and prognostic value of baseline PSMA-PET total tumor volume and SUV mean within ENZA-p, a randomized phase II trial of enzalutamide versus enzalutamide plus [ 177 Lu] Lu-PSMA-617 (ANZUP1901)Emmett, Louise, Papa, Nathan, Subramaniam, Shalini, Crumbaker, Megan, Joshua, Anthony M., Nguyen, Andrew, Weickhardt, Andrew James, Lee, Sze Ting, Ng, Siobhan, Francis, Roslyn J., Goh, Jeffrey C., Pattison, David A., Tan, Thean Hsiang, Kirkwood, Ian David, Hofman, Michael S., Sandhu, Shahneen, Martin, Andrew James, Thomas, Hayley, Davis, Ian D., Stockler, Martin R. and The Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) (2025). Predictive and prognostic value of baseline PSMA-PET total tumor volume and SUV mean within ENZA-p, a randomized phase II trial of enzalutamide versus enzalutamide plus [ 177 Lu] Lu-PSMA-617 (ANZUP1901). 2025 ASCO Annual Meeting, Chicago, IL, United States, 30 May - 3 June 2025. Alexandria, VA, United States: American Society of Clinical Oncology. doi: 10.1200/jco.2025.43.16_suppl.5011 |
|
2025 Journal Article Lutetium-177-PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trialKwan, Edmond M., Ng, Sarah W. S., Tolmeijer, Sofie H., Emmett, Louise, Sandhu, Shahneen, Buteau, James P., Iravani, Amir, Joshua, Anthony M., Francis, Roslyn J., Subhash, Vinod, Lee, Sze-Ting, Scott, Andrew M., Martin, Andrew J., Stockler, Martin R., Donnellan, Grainne, Annala, Matti, Herberts, Cameron, Davis, Ian D., Hofman, Michael S., Azad, Arun A., Wyatt, Alexander W., Akhurst, Tim, Alipour, Ramin, Bailey, Dale L., Banks, Patricia, Beaulieu, Alexis, Campbell, Louise, Chua, Wei, Crumbaker, Megan ... Zhang, Alison Y. (2025). Lutetium-177-PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial. Nature Medicine, 2025 (8), 1-15. doi: 10.1038/s41591-025-03704-9 |
|
2025 Journal Article Association of the circulating lipid panel, PCPro, with clinical outcomes in metastatic hormone-sensitive prostate cancer: post-hoc analysis of the ENZAMET Phase 3 randomised trial (ANZUP 1304)Lin, H.-M., Scheinberg, T., Portman, N., Kim, R.M.N., Mellor, R., Hunyh, K., Faulkner, A.N., Mellett, N.A., Davis, I.D., Martin, A., Sullivan, D., Joshua, A., McJannett, M., Subhash, V., Yip, S., Azad, A.A., Marschner, I.C., North, S.A., McDermott, R.S., Chi, K.N., Stockler, M.R., Sweeney, C.J., Meikle, P.J. and Horvath, L.G. (2025). Association of the circulating lipid panel, PCPro, with clinical outcomes in metastatic hormone-sensitive prostate cancer: post-hoc analysis of the ENZAMET Phase 3 randomised trial (ANZUP 1304). Annals of Oncology, 36 (9), 1068-1077. doi: 10.1016/j.annonc.2025.05.529 |
|
2025 Journal Article Can we use viral receptor mapping and particle deposition models to predict the clinical severity of novel airborne pathogens?Pillay, Kineshta, Marr, Linsey C., Henriques, Andre, Martin, Andrew R., Prussin, Aaron J., Aleixo, Luis, Andreini, Marco, Mounet, Nicolas, Finlay, Warren H. and Tang, Julian W. (2025). Can we use viral receptor mapping and particle deposition models to predict the clinical severity of novel airborne pathogens?. Clinical Microbiology and Infection, 31 (4), 503-505. doi: 10.1016/j.cmi.2024.11.005 |
|
2025 Journal Article Targeted Long-Read Sequencing as a Single Assay Improves the Diagnosis of Spastic-Ataxia DisordersRudaks, Laura Ivete, Stevanovski, Igor, Yeow, Dennis, Reis, Andre L. M., Chintalaphani, Sanjog R., Cheong, Pak Leng, Gamaarachchi, Hasindu, Worgan, Lisa, Ahmad, Kate, Hayes, Michael, Hannaford, Andrew, Kim, Samuel, Fung, Victor S. C., Halmagyi, Gabor M., Martin, Andrew, Manser, David, Tchan, Michel, Ng, Karl, Kennerson, Marina L., Deveson, Ira W. and Kumar, Kishore Raj (2025). Targeted Long-Read Sequencing as a Single Assay Improves the Diagnosis of Spastic-Ataxia Disorders. Annals of Clinical and Translational Neurology, 12 (4), 832-841. doi: 10.1002/acn3.70008 |
|
2025 Conference Publication Overall survival and quality of life with [ <sup>177</sup> Lu] Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in poor-risk, metastatic, castration-resistant prostate cancer in ENZA-p (ANZUP 1901)Emmett, Louise, Subramaniam, Shalini, Crumbaker, Megan, Nguyen, Andrew, Joshua, Anthony M., Weickhardt, Andrew James, Lee, Sze Ting, Ng, Siobhan, Francis, Roslyn J., Goh, Jeffrey C., Pattison, David A., Tan, Thean Hsiang, Kirkwood, Ian David, Sandhu, Shahneen, Zhang, Alison Yan, Hofman, Michael S., Thomas, Hayley, Martin, Andrew James, Davis, Ian D., Stockler, Martin R. and The Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) (2025). Overall survival and quality of life with [ 177 Lu] Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in poor-risk, metastatic, castration-resistant prostate cancer in ENZA-p (ANZUP 1901). 2025 ASCO Genitourinary Cancers Symposium, San Francisco, CA United States, 13-15 February 2025. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2025.43.5_suppl.17 |
|
2025 Journal Article Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trialEmmett, Louise, Subramaniam, Shalini, Crumbaker, Megan, Joshua, Anthony M, Sandhu, Shahneen, Nguyen, Andrew, Weickhardt, Andrew, Lee, Sze-Ting, Ng, Siobhan, Francis, Roslyn J, Goh, Jeffrey C, Pattison, David A, Tan, Thean Hsiang, Kirkwood, Ian D, Gedye, Craig, Rutherford, Natalie K, Kumar, Aravind S Ravi, Pook, David, Ramdave, Shakher, Nadebaum, David P, Voskoboynik, Mark, Redfern, Andrew D, Macdonald, William, Krieger, Laurence, Schembri, Geoff, Chua, Wei, Lin, Peter, Horvath, Lisa, Bastick, Patricia ... Bills, Madison (2025). Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial. The Lancet Oncology, 26 (3), 291-299. doi: 10.1016/s1470-2045(25)00009-9 |
|
2025 Journal Article Enzalutamide with standard first-line therapy for metastatic hormone-sensitive prostate cancer: a plain language summary of the ENZAMET trial (ANZUP 1304)Conduit, Ciara, Inderjeeth, Andrisha-Jade, Allen, Raymond, Martin, Andrew J., Parulekar, Wendy, Mulroe, Eibhlin, McJannett, Margaret, Zielinski, Robert R., Thomson, Alastair, Tan, Thean Hsiang, Sandhu, Shahneen K., Reaume, M. Neil, Pook, David W., North, Scott A., Marx, Gavin M., Joshua, Anthony, Horvath, Lisa, McDermott, Ray, Chowdhury, Simon, Chi, Kim N., Zhang, Alison Y., Stockler, Martin R., Davis, Ian D., Sweeney, Christopher J. and on behalf of ANZUP Cancer Trials Group (2025). Enzalutamide with standard first-line therapy for metastatic hormone-sensitive prostate cancer: a plain language summary of the ENZAMET trial (ANZUP 1304). Future Oncology, 21 (6), 627-636. doi: 10.1080/14796694.2024.2440277 |
|
2025 Journal Article Balancing precision and affordability in assessing infant development in large-scale mortality trials: Secondary analysis of a randomised controlled trialRobledo, Kristy P., Rieger, Ingrid, Finlayson, Sarah, Tarnow-Mordi, William and Martin, Andrew J. (2025). Balancing precision and affordability in assessing infant development in large-scale mortality trials: Secondary analysis of a randomised controlled trial. Archives of Disease in Childhood: Fetal and Neonatal Edition, 110 (4), F409-F414. doi: 10.1136/archdischild-2024-327762 |
|
2025 Journal Article Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trialEmmett, Louise, Papa, Nathan, Subramaniam, Shalini, Crumbaker, Megan, Nguyen, Andrew, Joshua, Anthony M, Sandhu, Shahneen, Weickhardt, Andrew, Lee, Sze-Ting, Ng, Siobhan, Francis, Roslyn J, Goh, Jeffrey C, Pattison, David A, Tan, Thean Hsiang, Kirkwood, Ian D, Ayati, Narjess, Niu, Claire, Hofman, Michael S, Martin, Andrew James, Thomas, Hayley, Davis, Ian D and Stockler, Martin R (2025). Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial. The Lancet Oncology, 26 (9), 1168-1177. doi: 10.1016/S1470-2045(25)00339-0 |
|
2024 Journal Article Understanding regional aerosol deposition in pediatric airways during oral breathing: Insights from computational modelingPillay, Kineshta, Finlay, Warren H. and Martin, Andrew R. (2024). Understanding regional aerosol deposition in pediatric airways during oral breathing: Insights from computational modeling. Journal of Aerosol Science, 182 106438. doi: 10.1016/j.jaerosci.2024.106438 |
|
2024 Journal Article INTEGRATE IIa Phase III Study: Regorafenib for refractory advanced gastric cancerPavlakis, Nick, Shitara, Kohei, Sjoquist, Katrin, Martin, Andrew, Jaworski, Anthony, Tebbutt, Niall, Bang, Yung-Jue, Alcindor, Thierry, O'Callaghan, Chris, Strickland, Andrew, Rha, Sun Young, Lee, Keun-Wook, Kim, Jin-Soo, Bai, Li-Yuan, Hara, Hiroki, Oh, Do-Youn, Yip, Sonia, Zalcberg, John, Price, Tim, Simes, John and Goldstein, David (2024). INTEGRATE IIa Phase III Study: Regorafenib for refractory advanced gastric cancer. Journal of Clinical Oncology, 43 (4), 453-463. doi: 10.1200/jco.24.00055 |
|
2024 Conference Publication EV430/#358 Benefit-harm trade-off for groin node dissection versus groin ultrasound monitoring to reduce the risk of surgery-related morbidity in vulvar cancer – a decision-tree analysisObermair, Andreas, West, Zoe, Baxter, Eva, Condous, George, Hacker, Neville, Lord, Sally, Mccarthy, Sandie, Janda, Monika, Tuffaha, Haitham, Hayes, Sandi, Disipio, Tracey, Mellon, Anne, Gebski, Val, Mcnally, Orla and Martin, Andrew (2024). EV430/#358 Benefit-harm trade-off for groin node dissection versus groin ultrasound monitoring to reduce the risk of surgery-related morbidity in vulvar cancer – a decision-tree analysis. IGCS 2024 Annual Meeting, Dublin, Ireland, 16-18 October 2024. London, United Kingdom: BMJ Group. doi: 10.1136/ijgc-2024-igcs.551 |
